Lifetimes, transition probabilities, and level energies in Fe I

We use time-resolved laser-induced fluorescence to measure the lifetime of 186 Fe levels with energies between 25 900 and 60 758 cm . Measured emission branching fractions for these levels yield transition probabilities for 1174 transitions in the range 225-2666 nm. We find another 640 Fe transition probabilities by interpolating level populations in the inductively coupled plasma spectral source. We demonstrate the reliability of the interpolation method by comparing our transition probabilities with absorption oscillator strengths measured by the Oxford group [Blackwell et al., Mon. Not. R. Astron. Soc. 201, 595-602 (1982)]. We derive precise Fe level energies to support the automated method that is used to identify transitions in our spectra

Oxygen Abundances in Two Metal-Poor Subgiants from the Analysis of the 6300 A Forbidden O I Line

Recent LTE analyses (Israelian et al. 1998 and Bosegaard et al. 1999) of the OH bands in the optical-ultraviolet spectra of nearby metal-poor subdwarfs indicate that oxygen abundances are generally higher than those previously determined. The difference increases with decreasing metallicity and reaches delta([O/Fe]) ~ +0.6 dex as [Fe/H] approaches -3.0. Employing high resolution (R = 50000), high S/N (~ 250) echelle spectra of the two stars found by Israelian et al. (1998) to have the highest [O/Fe]-ratios, viz, BD +23 3130 and BD +37 1458, we conducted abundance analyses based on about 60 Fe I and 7-9 Fe II lines. We determined from Kurucz LTE models the values of the stellar parameters, as well as abundances of Na, Ni, and the traditional alpha-elements, independent of the calibration of color vs $T_{eff}$ scales. We determined oxygen abundances from spectral synthesis of the stronger line (6300 A) of the [O I] doublet. The syntheses of the [O I] line lead to smaller values of [O/Fe], consistent with those found earlier among halo field and globular cluster giants. We obtain [O/Fe] = +0.35 +/- 0.2 for BD +23 3130 and +0.50 +/- 0.2 for BD +37 1458. In the former, the [O I] line is very weak (~ 1 mA), so that the quoted [O/Fe] value may in reality be an upper limit. Therefore in these two stars a discrepancy exists between the [O/Fe]- ratios derived from [O I] and the OH feature, and the origin of this difference remains unclear. Until the matter is clarified, we suggest it is premature to conclude that the ab initio oxygen abundances of old, metal-poor stars need to be revised drastically upward.Comment: 38 pages, 5 tables, 14 figures To appear in July 1999 AJ Updated April 16, 1999. Fixed typo

A quantitative investigation for deployment of mobile collaborative robots in high-value manufacturing

Component inspection is often the bottleneck in high-value manufacturing, driving industries like aerospace toward automated inspection technologies. Current systems often employ fixed arm robots, but they lack the flexibility in adapting to new components or orientations Advanced mobile robotic platforms with updated sensor technologies and algorithms have improved localization and path planning capabilities, making them ideal for bringing inspection processes directly to parts. However, mobile platforms introduce challenges in localization and maneuverability, leading to potential errors. Their positional uncertainty is higher than fixed systems due to the lack of a fixed calibrated location, posing challenges for position-sensitive inspection sensors. Therefore, it's essential to assess the positional accuracy and repeatability of mobile manipulator platforms. The KUKA KMR iiwa was chosen for its collaborative features, robust build, and scalability within the KUKA product range. The accuracy and repeatability of the mobile platform were evaluated through a series of tests to evaluate the performance of its integrated feature mapping, the effect of various speeds on positional accuracy, and the efficiency of the omnidirectional wheels for a range of translation orientations. Experimental evaluation revealed that enabling feature mapping substantially improves the KUKA KMR iiwa's performance, with accuracy gains and error reductions exceeding 90%. Repeatability errors were under 7 mm with mapping activated and around 2.5 mm in practical scenarios, demonstrating that mobile manipulators, incorporating both the manipulator and platform, can fulfil the precise requirements of industries with high precision needs. Providing a highly diverse alternative to traditional fixed-base industrial manipulators

Systems Analysis Unfolds the Relationship between the Phosphoketolase Pathway and Growth in Aspergillus nidulans

Background: Aspergillus nidulans is an important model organism for studies on fundamental eukaryotic cell biology and on industrial processes due to its close relation to A. niger and A. oryzae. Here we identified the gene coding for a novel metabolic pathway in A. nidulans, namely the phosphoketolase pathway, and investigated the role of an increased phosphoketolase activity. Methodology/Principal Findings: Over-expression of the phosphoketolase gene (phk) improved the specific growth rate on xylose, glycerol and ethanol. Transcriptome analysis showed that a total of 1,222 genes were significantly affected by overexpression of the phk, while more than half of the affected genes were carbon source specific. During growth on glucose medium, the transcriptome analysis showed that the response to phk over-expression is targeted to neutralize the effect of the over-expression by regulating the acetate metabolism and initiate a growth dampening response. Conclusions/Significance: Metabolic flux analysis using 13C-labelled glucose, showed that over-expression of phosphoketolase added flexibility to the central metabolism. Our findings further suggests that A. nidulans is not optimized for growth on xylose, glycerol or ethanol as the sole carbon sources. © 2008 Panagiotou et al.published_or_final_versio

HEGPOL: Randomized, placebo controlled, multicenter, double-blind clinical trial to investigate hepatoprotective effects of glycine in the postoperative phase of liver transplantation [ISRCTN69350312]

BACKGROUND: Kupffer cell-dependent ischemia / reperfusion (I/R) injury after liver transplantation is still of high clinical relevance, as it is strongly associated with primary dysfunction and primary nonfunction of the graft. Glycine, a non-toxic, non-essential amino acid has been conclusively shown in various experiments to prevent both activation of Kupffer cells and reperfusion injury. Based on both experimental and preliminary clinical data this study protocol was designed to further evaluate the early effect of glycine after liver transplantation. METHODS / DESIGN: A prospective double-blinded randomized placebo-controlled multicenter study with two parallel groups in a total of 130 liver transplant recipients was designed to assess the effect of multiple intravenous doses of glycine after transplantation. Primary endpoints in hierarchical order are: peak levels of both aspartat-amino-transaminase (AST) and alanine-amino-transaminase (ALT) as surrogates for the progression of liver related injury, as well as both graft and patient survival up to 2 years after transplantation. Furthermore, the effect of glycine on cyclosporine A-induced nephrotoxicity is evaluated. DISCUSSION: The ongoing clinical trial represents an advanced element of the research chain, along which a scientific hypothesis has to go by, in order to reach the highest level of evidence; a randomized, prospective, controlled double-blinded clinical trial. If the data of this ongoing research project confirm prior findings, glycine would improve the general outcome after liver transplantation

A-type Supergiant Abundances in the SMC: Probes of Evolution

New abundances of N, O, Na, Mg, Si, Ca, Sc, Ti, Cr, Fe, Sr, Zr, and Ba are presented for 10 A-type supergiants in the SMC, plus upper limits for C. In interpreting the CNO results for constraints on stellar evolution theories, careful attention has been paid to the comparison abundances, i.e., the present day abundances of SMC nebulae and B-dwarf stars. These new results are also compared to published results from F-K supergiant analyses, and found to be in good agreement when both sets of data are carefully examined as differential (SMC minus Galactic standard) abundances. With the exception of nitrogen, very small star-to-star abundance variations are found for all elements in this analysis. The N variations are not predicted by standard stellar evolution models. Instead, the results support the new predictions reported from rotating stellar models, where the range in nitrogen is the result of partial mixing of CN-cycled gas from the stellar interior due to main-sequence rotation at different rates (c.f., Langer & Heger 1998). The overall overabundance of nitrogen in the sampled stars also implies these stars have undergone the first dredge-up in addition to having been mixed while on the main-sequence. The alpha-elements (O, Mg, Si, Ca, Ti) have similar underabundances to Fe, which is not the same as seen in metal-poor stars in the solar neighborhood of the Galaxy. In addition, certain light s-process elements (Zr, Ba) are slightly more underabundant than Fe, which is predicted by the bursting chemical evolution model presented by Pagel & Tautvaisiene (1998) for the SMC.Comment: Accepted for publication in the Astrophysical Journal, Manuscript #39295. Accepted January 4, 199

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None

Status Update and Interim Results from the Asymptomatic Carotid Surgery Trial-2 (ACST-2)

Objectives: ACST-2 is currently the largest trial ever conducted to compare carotid artery stenting (CAS) with carotid endarterectomy (CEA) in patients with severe asymptomatic carotid stenosis requiring revascularization. Methods: Patients are entered into ACST-2 when revascularization is felt to be clearly indicated, when CEA and CAS are both possible, but where there is substantial uncertainty as to which is most appropriate. Trial surgeons and interventionalists are expected to use their usual techniques and CE-approved devices. We report baseline characteristics and blinded combined interim results for 30-day mortality and major morbidity for 986 patients in the ongoing trial up to September 2012. Results: A total of 986 patients (687 men, 299 women), mean age 68.7 years (SD ± 8.1) were randomized equally to CEA or CAS. Most (96%) had ipsilateral stenosis of 70-99% (median 80%) with contralateral stenoses of 50-99% in 30% and contralateral occlusion in 8%. Patients were on appropriate medical treatment. For 691 patients undergoing intervention with at least 1-month follow-up and Rankin scoring at 6 months for any stroke, the overall serious cardiovascular event rate of periprocedural (within 30 days) disabling stroke, fatal myocardial infarction, and death at 30 days was 1.0%. Conclusions: Early ACST-2 results suggest contemporary carotid intervention for asymptomatic stenosis has a low risk of serious morbidity and mortality, on par with other recent trials. The trial continues to recruit, to monitor periprocedural events and all types of stroke, aiming to randomize up to 5,000 patients to determine any differential outcomes between interventions. Clinical trial: ISRCTN21144362. © 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved

Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)

Despite widespread availability of a large body of evidence in the area of hypertension, the translation of that evidence into viable recommendations aimed at improving the quality of health care is very difficult, sometimes to the point of questionable acceptability and overall credibility of the guidelines advocating those recommendations. The scientific community world-wide and especially professionals interested in the topic of hypertension are witnessing currently an unprecedented debate over the issue of appropriateness of using different drugs/drug classes for the treatment of hypertension. An endless supply of recent and less recent "drug-news", some in support of, others against the current guidelines, justifying the use of selected types of drug treatment or criticising other, are coming out in the scientific literature on an almost weekly basis. The latest of such debate (at the time of writing this paper) pertains the safety profile of ARBs vs ACE inhibitors. To great extent, the factual situation has been fuelled by the new hypertension guidelines (different for USA, Europe, New Zeeland and UK) through, apparently small inconsistencies and conflicting messages, that might have generated substantial and perpetuating confusion among both prescribing physicians and their patients, regardless of their country of origin. The overwhelming message conveyed by most guidelines and opinion leaders is the widespread use of diuretics as first-line agents in all patients with blood pressure above a certain cut-off level and the increasingly aggressive approach towards diagnosis and treatment of hypertension. This, apparently well-justified, logical and easily comprehensible message is unfortunately miss-obeyed by most physicians, on both parts of the Atlantic. Amazingly, the message assumes a universal simplicity of both diagnosis and treatment of hypertension, while ignoring several hypertension-specific variables, commonly known to have high level of complexity, such as: - accuracy of recorded blood pressure and the great inter-observer variability, - diversity in the competency and training of diagnosing physician, - individual patient/disease profile with highly subjective preferences, - difficulty in reaching consensus among opinion leaders, - pharmaceutical industry's influence, and, nonetheless, - the large variability in the efficacy and safety of the antihypertensive drugs. The present 2-series article attempts to identify and review possible causes that might have, at least in part, generated the current healthcare anachronism (I); to highlight the current trend to account for the uncertainties related to the fixed blood pressure cut-off point and the possible solutions to improve accuracy of diagnosis and treatment of hypertension (II)